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of population, economic & ﬁ nancial information, organization, prescription pattern 
and patient management. We ﬁ rst ran a principal component analysis on quantitative 
variables and then a multiple correspondence analysis on qualitative variables, in order 
to get individuals coordinates of PCTs on several axes on which they were projected. 
We then merged the results, and ran an analysis to create PCTs clusters. RESULTS: 
We identiﬁ ed 5 clusters of PCTs with differentiated, homogeneous attitude towards 
innovative drugs. Cluster 1 focused on MH disorders with GP-level decision-making, 
cluster 2 focused on MH disorders and contained high-prescribing physicians, cluster 
3 had low recognition of MH disorders, cluster 4 had low recognition but offered a 
high level of care while cluster 5 was focused on cost containment. The clusters also 
varied in population size from 1.2 M to 23.9 M. CONCLUSIONS: As this work was 
rather innovative it was validated by local pharmaceutical sales and marketing orga-
nization. The cluster approach proposed was endorsed by account managers’ prag-
matic experience in the ﬁ eld and correlated well with their experience of obtaining 
access for their innovative MH drugs. This study helped to improve our understanding 
of the UK landscape in patient access for innovative drugs in MH.
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OBJECTIVES: Attention-Deﬁ cit/Hyperactivity Disorder (ADHD) is a neurobehavioral 
developmental disorder, that is characterized by hyperactivity and impulse control 
disorder. In Germany pharmaceutical therapy is approved for children and adolescents 
solely. Therefore, treating adult patients with ADHD complies with off-label use of 
stimulants. Aim of this Health Technology Assessment is to examine the clinical 
effectiveness, cost-effectiveness, ethical-social and legal aspects of pharmacotherapy 
(stimulants, antidepressants, norepinephrine reputake inhibitors) of adult ADHD 
patients. METHODS: A systematic literature research is conducted in relevant elec-
tronic literature databases. Studies matching the ex ante deﬁ ned inclusion criteria are 
assessed systematically and qualitatively according to methodical standards by two 
reviewers. Due to heterogeneity of included studies no meta-analysis is performed. 
RESULTS: Nine randomised controlled trials (RCT), ﬁ ve systematic reviews, three 
economic and two studies concerning legal aspects are included. All RCT show 
improvement regarding ADHD symptoms (hyperactivity, impulsivity). Response rates 
vary between 7 % and 42 % in the control group and 17 % to 59,6 % in the inter-
vention group. The studies use primarily investigator and self-rated questionnaires 
such as the ADHD Rating Scale, the Conners Scales and the Clinical Global Impression 
as outcome parameters for the core symptoms of ADHD. Some studies show a larger 
improvement of the ADHD symptoms by a ﬂ exible dose approach. The systematic 
reviews demonstrate statistically signiﬁ cant improvement in symptoms of ADHD 
compared to placebo and other medications. The effect sizes for stimulants are some-
what higher than for non-stimulants. Adult ADHD patients cause higher annual direct 
and indirect costs than matched controls. The average medical costs are reported with 
1.262 US-Dollar in 1998 and 1.673 US-Dollar in 2001. CONCLUSIONS: Method-
ological limitations of the RCT are the short study duration and the high drop-out 
rates. Further research is needed to determine the cost-effectiveness of medical treat-
ment of adult ADHD patients.
PMH66
PREVALENCE OF AFFECTIVE DISORDERS IN SOUTH-WEST REGION OF 
SWEDEN
Löfroth E, Myrén KJ, Bruce S, Dahlberg E
IMS Health, Stockholm, Sweden
OBJECTIVES: To determine the prevalence of affective disorders (section F3 in 
ICD-10) in South-West region of Sweden. METHODS: This was a retrospective 
longitudinal descriptive database study of the utilization of health care of patients 
from the South-West region of Sweden (1.5 million inhabitants). All patients who were 
diagnosed with affective disorders between 2001 and 2007 in the South-West region 
of Sweden were included in the study. The patients were diagnosed in primary-, in- and 
out-patient care. RESULTS: A total of 138,194 patients were diagnosed with at least 
one type of affective disorder. This corresponded to a prevalence of 9% in the popula-
tion of South-West region in Sweden. 89 percent (123,524 patients) of the total sample 
were diagnosed with major depressive disorder (F32) followed by recurrent depressive 
disorder (F33) at 14% (19,944 patients). Bipolar affective disorder (F31) was diag-
nosed in 5% of the patients (6932) and unspeciﬁ ed mood (affective) disorder (F39) 
was diagnosed in 4% of the patients (5,431). The prevalence of the different diagnoses 
were 8 percent for depressive episode, 1 percent for recurrent depressive disorder, 0.5 
percent for bipolar affective disorder, 0.4% for unspeciﬁ ed mood (affective) disorder. 
CONCLUSIONS: Depressive episode was by far the most common of the affective 
disorders diagnosed, with a prevalence of 8 percent. a question remains whether the 
prevalence for bipolar is underestimated as this study found it to be 0.5%. The 
expected prevalence for bipolar disorder is 1 percent of the population. One plausible 
explanation could be that bipolar patients are classiﬁ ed with other codes than F31 in 
the South-West region of Sweden.
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OBJECTIVES: Despite the use of antipsychotics to treat dementia patients, the efﬁ cacy 
of the treatment is not well established. We examine factors associated with antipsy-
chotics use among community-dwelling older persons with dementia. METHODS: 
We used data from The Aging, Demographics, and Memory Study (ADAMS) to assess 
dementia severity and service use from 2002 to 2004. We used logistic regressions to 
identify factors associated with antipsychotic use; N = 307. RESULTS: Among older 
persons with dementia living in community (weighted sample = 207,544), 7.8% 
(weighted sample = 16,272) took any antipsychotic medications; 69.1% were female, 
70.7% were white, and 21.8% were African American. The average age was 85 years. 
Physical functions were measured by the number of ADL (average. 2.9) and number 
of IADL (mean 3.6). The most frequent primary diagnoses were Alzheimer’s disease 
(74.3%), vascular dementia (16.0%) and other dementia (9.8%).The most frequently 
prescribed antipsychotics were: risperidone (58.0%), quetiapine (15.4%), and halo-
peridol (7.7%). Of those taking an antipsychotic, 86.0% were diagnosed with 
Alzheimer’s dementia. We used the Neuropsychiatry Inventory (NPI) for behavior 
problems (delusions, hallucinations, agitation/aggression, depression, apathy, elation, 
anxiety, disinhibition, irritability/lability, and aberrant motor behavior). We evaluated 
severity of dementia using the Clinical Dementia Rating Scale (CDR).Community-
dwelling older persons with dementia are signiﬁ cantly more likely to receive antipsy-
chotics if they were agitated (OR = 3.4, P < 0.05), had disinhibition (OR = 4.6, P < 
0.05), or had greater dementia severity (OR = 1.9, P < 0.01). Also, Medicaid recipients 
were signiﬁ cantly more likely to receive antipsychotic medications (OR = 5.4, P < 
0.01). Participants were signiﬁ cantly less likely to be medicated with antipsychotics if 
they had vascular dementia (OR = 0.09, P < 0.05) or the caregivers were clinically 
depressed (OR = 0.2, P < 0.05). CONCLUSIONS: Community-dwelling older persons 
with dementia are more likely to receive antipsychotics if caregivers report behavior 
problems, the dementia is more advanced, and the patient has Medicaid coverage. 
Persons with vascular dementia are less likely to be treated with antipsychotics.
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OBJECTIVES: Treatment discontinuation in psychiatric care is a major cause for the 
deterioration of mental health problems. This study assessed reasons for treatment 
discontinuation of patients suffering from schizophrenia or depression in a local 
mental health care system in Germany. METHODS: A retrospective survey was per-
formed to assess how coordination of care through mental health care providers in 
the Rhein-Kreis-Neuss region (Germany) is organized. Within this survey reasons for 
treatment discontinuation were explored from the perspective of providers and 
patients. 88 providers of care (60 institutions) and 30 patients diagnosed with schizo-
phrenia and 17 patients diagnosed with major depression were interviewed using in-
depth face-to-face interviews. Additionally providers were qualitatively interviewed 
on strategies to prevent discontinuations. RESULTS: Providers were asked to rank 
pre-speciﬁ ed reasons for treatment discontinuation according to their occurrence 
(often, occasionally, seldom, never). 38.8 % ranked non-adherence to medication as 
often, 38.1 % waiting times for next treatment. 25.6 % identiﬁ ed problems in the 
patient’s social environment as being often a reason for treatment discontinuation, 
23.7 % mentioned revolving doors effects, 19.3 % resistance to therapy and 12.3 % 
lack of communication between providers. Patients diagnosed with schizophrenia 
(mean age 45 years; mean duration of illness 16 years) and depression (mean age 45 
years; mean duration of illness 13 years) indicated that they consider discontinuation 
or actually discontinue treatment when there is a lack of social integration or when 
there is no reaction of providers to articulated problems with treatments. In response 
to an open question on suggestions for improvement, providers recommended better 
cross-sectoral coordination, earlier start of treatment and early return to normal daily 
living as appropriate measures. CONCLUSIONS: From the subjective perspective of 
providers and patients a variety of causes seem to inﬂ uence treatment discontinuation. 
More research into speciﬁ c interventions to improve treatment adherence is needed.
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OBJECTIVES: To assess if patients suffering from schizophrenia or depression are 
affected by waiting times for the next treatment in a mental health care system in 
Germany. METHODS: Aa retrospective survey was performed to assess coordination 
of care through providers engaged in the care for patients with schizophrenia or major 
depression in the Rhein-Kreis-Neuss region (Germany). One parameter for evaluating 
quality of coordination is the occurrence of waiting times, emerging when patients are 
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transferred from one point of care to the next with treatment continuation potentially 
being delayed. 88 providers of care (60 institutions), 30 patients diagnosed with 
schizophrenia and 17 patients diagnosed with depression were surveyed through in-
depth interviews. The total number of questions was 56 for providers, and 54 ques-
tions for patients. RESULTS: A total of 56% of patients diagnosed with schizophrenia 
(mean age 45 years, mean duration of illness 16 years) experience waiting times when 
transferred to an outpatient rehabilitation center, 50% while being transferred to an 
institution of assisted working or to a place of sheltered living (33%). Patients diag-
nosed with major depression (mean age 45 years; mean duration of illness 13 years) 
experience waiting times when transferred to an institution of assisted working (63%), 
to an outpatient rehabilitation center (57%) or to a psychotherapist (56%). Providers 
experience waiting times when they transfer patients to psychotherapists (55%). a 
total of 40% of patients diagnosed with schizophrenia and 58% of patients diagnosed 
with major depression perceive waiting times as heavily constraining, affecting their 
treatment and care, and potentially leading to a setback in their treatment progress. 
Providers see capacity constraints as main reason for waiting times. CONCLUSIONS: 
This study describes waiting times in coordination of mental health care between 
different providers as a problem. Potential negative effects on treatment success show 
the need for optimization. 
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OBJECTIVES: The Alcohol Dependence Scale (ADS) is a quantitative measure of the 
severity of alcohol dependence consistent with the concept of the alcohol dependence 
syndrome. The 25 items cover alcohol withdrawal symptoms, impaired control over 
drinking, awareness of a compulsion to drink, increased tolerance to alcohol, and 
salience of drink-seeking behavior. This study aims to adapt the ADS questionnaire 
into Turkish culture and check the reliability and validity of the questionnaire cultur-
ally. METHODS: The original instrument was translated and back translated by two 
independent translators. For psychometric measures, a small sample was used to check 
the initial comprehension and factibility. Cronbach’s Alfa was used to assess reliability 
and factor analysis to assess dimensionality. The EuroQol questionnaire and corre-
sponding Visual Analogue Scales were used for concurrent validity. RESULTS: A total 
of 200 students between the ages of 19–28 were participated in the study. Mean age 
was 22. The internal consistency coefﬁ cient (Cronbach’s alpha) of ADS was 0.92. 
Factor analysis of the scale revealed that it was composed of six factors with Eigen-
values >1.0, accounting for 74 % of the total variance. Correlations were moderate 
with EuroQol and VAS. CONCLUSIONS: The culturally adapted Alcohol Depen-
dence Scale has good validity and reliability. The instrument is likely to be suitable 
for the evaluation of alcohol dependence of people in Turkey.
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OBJECTIVES: In health economics, cost-effectiveness analyses are performed based 
on standardized established methods expressing outcomes in terms of costs per qual-
ity-adjusted life-year (QALY). In the ﬁ eld of care for criminal youth, interventions are 
increasingly drawn into the medical domain and towards reimbursement protocols so 
that a common cost-effectiveness measure becomes a necessity. However, cost-effec-
tiveness of these interventions has so far not been expressed in terms of cost per QALY, 
but in terms of clinical measures. The aim of this study is to explore the applicability 
of the QALY as effect measure of interventions for criminal youth. METHODS: The 
112 juvenile delinquents between 12 and 18 years included in this study were recruited 
at the start of Functional Family Therapy (FFT) from ﬁ ve mental health institutions 
in The Netherlands. Treatment efﬁ cacy was assessed using clinical outcome measures 
SDQ, YSR, CBCL, and PACS. Quality of life was measured using EuroQol EQ-5D. 
Data was analyzed to determine whether quality of life and clinical outcome measures 
show a signiﬁ cant correlation. Dutch population EQ-5D data was consulted to deter-
mine whether EQ-5D sufﬁ ciently captures differences between criminal and non-
criminal groups. RESULTS: Comparison between groups of criminal and non-criminal 
youths yielded no signiﬁ cant differences for juvenile delinquents or their parents. 
Correlation between several clinical outcome measures and EQ-5D scores of delin-
quent youths has been found suggesting that EQ-5D captures some differences in 
criminal behaviour. CONCLUSIONS: The study conﬁ rms the expected correlation 
between several classical forensic effect measures and general health economics out-
comes, but several aspects were not reﬂ ected by the QALY. Furthermore, the QALY 
measure insufﬁ ciently distinguishes between criminal and non criminal groups. We 
suggest further research before considering the application of the QALY as an effect 
measure for delinquent youths.
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BACKGROUND: High placebo response is observed in trials measuring subjective 
outcomes as in the case of GAD. This contributes to investigational drug failure owing 
to lack of differentiation between intervention and control group. Placebo run-in is 
frequently used to eliminate early responders however this has been criticised on the 
ground that it favours the active treatment. OBJECTIVES: To test the hypothesis that 
“The use of placebo run-in overestimates the treatment effect in placebo-controlled 
trials conducted in GAD”. METHODS: The Medline and EMBASE databases were 
searched to retrieve randomised, placebo-controlled trials conducted in adult GAD 
patients. Citations were screened on the basis of title and abstract and full text article 
of citations meeting eligibility criteria were sourced for detailed evaluation. Following 
this, citations reporting relevant outcomes were extracted using a pre-deﬁ ned extrac-
tion grid. Clinically relevant dichotomous outcomes: CGI-Improvement response, 
HAM-A response, and HAM-A remission were extracted. Considering heterogeneity 
among studies included, the random effects meta-analysis was performed in STATA 
9.0 using a standard meta-analysis approach. Results are presented as odds ratios with 
a 95% conﬁ dence interval. RESULTS: The literature search retrieved 1133 citations 
of which 41 were included following detailed evaluation (23 used placebo run-in 
phase). The point estimate for the relative treatment effect was similar (conﬁ dence 
interval overlap widely) irrespective of the use of placebo run-in phase (OR: 2.13 with 
run-in vs. 2.19 without run-in). Results were similar when individual outcomes were 
analyzed separately (HAM-A response OR: 2.17 vs. 2.14; CGI-I response OR: 2.20 
vs. 2.13; HAM-A remission OR: 1.98 vs. 2.05). CONCLUSIONS: Irrespective of 
outcomes considered, there was no statistically signiﬁ cant difference in the effect size 
between trials involving placebo run-in phase compared to those that did not. Our 
results do not support the hypothesis that the inclusion of placebo run-in overestimates 
the relative treatment effect in GAD. 
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OBJECTIVES: The study aimed to develop a standardized scale for co-morbidity 
assessment in Chronic Lymphocytic Leukaemia (CLL) patients to support physicians 
for selecting the optimal treatment according to the patient co-morbidity proﬁ le. 
METHODS: The co-morbidity scale was developed in four steps: a literature review 
to assess the existence of other scales and deﬁ ne the scale content; consensus meetings 
with ﬁ ve CLL experts to determine the content, format and weighting factor for each 
co-morbidity; a pilot study of 10 CLL patients to assess the scale feasibility; a meeting 
to agree the ﬁ nal version RESULTS: The literature review did not identify any existing 
scale but six papers related to assessment of CLL co-morbidities were selected. These 
allowed the initial selection of 21 diseases. In the expert meeting, the scale was reduced 
to 13 co-morbidities, with major impact on CLL treatment selection. Some additional 
variables (age, patient dependence and ECOG performance status) were added. Sub-
sequently, the ﬁ nal list of co-morbidities. variables and response options were agreed. 
The experts applied a weight factor to each co-morbidity, from 1 (minimal impor-
tance) to 3 (very important). a pilot study of 10 patients, using an electronic version 
of the scale, resulted in some changes but conﬁ rmed the scale’s feasibility. The ﬁ nal 
scale includes three sections. Part 1, the Functional Vital Scale, and a global assessment 
of the patient (not included in the global score). Part 2, the Co-morbidity scale, includ-
ing 11 co-morbidities weighted from 0 to 2 and scored from 0 (absence) to 2 (severe 
co-morbidity). Part 3, CLL alerts, is descriptive and includes the presence of splenec-
tomy and hypogammaglobulinemia. CONCLUSIONS: The co-morbidity scale is a 
tool to support the clinician in the selection of the optimal treatment for CLL patients. 
Further research is required to validate the scale and assess its beneﬁ ts.
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OBJECTIVES: Biologic treatment for severe forms of psoriasis proved to be effective 
and safety treatment in clinical trials. However, these drugs comprise a great ﬁ nancial 
burden. Therefore, we examined etanercept for treatment of severe forms of psoriasis 
in real clinical practice. METHODS: This was a prospective cohort non-interventional 
study of phase IV in real clinical practice which included 149 patients enrolled for 6 
months. Patients’ data were collected via electronic questionnaire. Clinical data (PASI 
score and BSA index), direct cost (inpatient and outpatient care, diagnostics, joint 
replacement etc.) and on QoL (expressed with EQ-5D and DLQI) were collected by 
